Refractory Metastatic Colorectal Cancer Clinical Trial
Official title:
NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer Will be intra-peritoneal infusion in Stage 1 and combined with intra-venous infusion in Stage 2. While in Stage 3, the investigators will expand to other cancer type at certain situation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04527068 -
QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05248048 -
NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer
|
Early Phase 1 | |
| Active, not recruiting |
NCT04737187 -
Phase III Study of Trifluridine/Tipiracil in Combination With Bevacizumab vs Trifluridine/Tipiracil Single Agent in Patients With Refractory Metastatic Colorectal Cancer
|
Phase 3 | |
| Recruiting |
NCT05205330 -
A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05733611 -
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
|
Phase 2 | |
| Completed |
NCT02860546 -
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
|
Phase 2 |